You are here

  • Home
  • Archive
  • Volume 75, Issue 4
  • Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial

Citation Tools

Article menu
Clinical and epidemiological research
Concise report
Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Sokolove J, Schiff M, Fleischmann R, et al
Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial
Annals of the Rheumatic Diseases 2016;75:709-714.